US Companies Launch CRISPR Clinical Trial
US Companies Launch CRISPR Clinical Trial
The Germany-based study will test an ex vivo genome-editing therapy for the inherited blood disorder β-thalassemia.
US Companies Launch CRISPR Clinical Trial
US Companies Launch CRISPR Clinical Trial

The Germany-based study will test an ex vivo genome-editing therapy for the inherited blood disorder β-thalassemia.

The Germany-based study will test an ex vivo genome-editing therapy for the inherited blood disorder β-thalassemia.

thalassemia
In Utero Transplant in First Clinical Trial Successful
In Utero Transplant in First Clinical Trial Successful
Jim Daley | May 30, 2018
Doctors treated the fetus, who has alpha thalassemia major, with cells from her mother’s bone marrow.
Technique Adapted from CRISPR-Cas9 Corrects Mutation in Human Embryos
Technique Adapted from CRISPR-Cas9 Corrects Mutation in Human Embryos
Catherine Offord | Sep 28, 2017
Researchers use base-editing to swap out an erroneous nucleotide responsible for a potentially life-threatening blood disorder.
CRISPR Corrects Blood Disorder Gene
CRISPR Corrects Blood Disorder Gene
Kerry Grens | Aug 5, 2014
Scientists use the genome-editing technique to fix a disease-causing mutation in human cell lines.